<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00031135</url>
  </required_header>
  <id_info>
    <org_study_id>FD-R-1994-01</org_study_id>
    <secondary_id>FD-R-001994-01</secondary_id>
    <nct_id>NCT00031135</nct_id>
  </id_info>
  <brief_title>Total Parenteral Nutrition-Associated Liver Disease</brief_title>
  <official_title>Prevention of TPN-Associated Hepatic Steatosis: A Placebo Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>FDA Office of Orphan Products Development</source>
  <brief_summary>
    <textblock>
      This is a study to determine whether choline, when added to total parenteral nutrition (TPN),&#xD;
      can help prevent the development of hepatic steatosis, a liver disease, in patients on TPN.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Choline deficiency-induced hepatic steatosis occurs in patients that require long-term TPN&#xD;
      and may progress to significant hepatic disease and death. Initial studies indicate&#xD;
      choline-supplemented TPN may reverse TPN-associated hepatic steatosis.&#xD;
&#xD;
      Choline chloride or placebo will be added to each patient's TPN for 16 weeks by the hospital&#xD;
      or pharmacy providing their usual TPN. Patients will receive their TPN in the hospital until&#xD;
      they are medically stable for discharge. If patients are discharged before study completion,&#xD;
      the pharmacy will deliver the TPN supply to them. Evaluation of hepatic steatosis is done by&#xD;
      CT scans and blood analyses. Blood will be drawn on a biweekly basis during the first 4 weeks&#xD;
      and at Week 8, 12, 16 or withdrawal. CT scans will be done at Week 4, 8, 16, or withdrawal.&#xD;
&#xD;
      Completion date provided represents the completion date of the grant per OOPD records&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>September 2001</start_date>
  <completion_date>September 2005</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Liver Diseases</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Choline Chloride</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Underlying pathology may include, but is not limited to: short bowel syndrome, chronic&#xD;
             pancreatitis, pancreatic pseudocysts, pseudo-obstruction, enterocutaneous fistula,&#xD;
             entero-enteric fistula, or malabsorption syndrome.&#xD;
&#xD;
          -  Requirement for TPN to supply greater than 85 percent of nutritional needs for at&#xD;
             least 16 weeks.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Not receiving lipid emulsion with TPN regimen&#xD;
&#xD;
          -  Albumin less than 2.5 g/L&#xD;
&#xD;
          -  Renal failure requiring hemo- or peritoneal dialysis&#xD;
&#xD;
          -  Hepatic failure (PT greater than 2 times control)&#xD;
&#xD;
          -  Diabetes&#xD;
&#xD;
          -  Hepatitis C&#xD;
&#xD;
          -  AIDS&#xD;
&#xD;
          -  Concurrent hospitalization for organ transplantation or rejection treatment&#xD;
&#xD;
          -  Concurrent cholinergic medication&#xD;
&#xD;
          -  Positive pregnancy test&#xD;
&#xD;
          -  Refusal to use an acceptable method of birth control&#xD;
&#xD;
          -  Ethanol abuse&#xD;
&#xD;
          -  More than 40 kcal/kg/day ideal body weight&#xD;
&#xD;
          -  Obesity with ensuing weight loss&#xD;
&#xD;
          -  Use of IV tetracycline, valproic acid, corticosteroids, methotrexate, or amiodarone&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2002</verification_date>
  <study_first_submitted>February 26, 2002</study_first_submitted>
  <study_first_submitted_qc>February 26, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2002</study_first_posted>
  <last_update_submitted>March 24, 2015</last_update_submitted>
  <last_update_submitted_qc>March 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2015</last_update_posted>
  <keyword>Parenteral Nutrition, Total</keyword>
  <keyword>Lipotropic Agents</keyword>
  <keyword>Choline</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Choline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

